Novartis Pharma AG: Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH) patients

Related Keywords

Paris ,France General ,France ,United States ,Switzerland ,America ,American ,Richard Jarvis ,Isabella Zinck ,Michael Meo ,Satoshi Sugimoto ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Mary Carmichael ,Ann Hematol ,Novartis Institutes For Biomedical Research ,Twitter ,Novartis ,Exchange Commission ,Greater Paris University Hospital ,Novartis Pharmaceuticals ,European Medicines Agency ,American Society Of Hematology Annual Meeting Exposition ,American Society ,Hematology Annual Meeting ,Peffault De Latour ,Saint Louis Hospital ,Greater Paris University ,Novartis Institutes ,Biomedical Research ,Therapy Designation ,Proximal Complement Inhibitor ,Has Superior Efficacy ,Intravenous Terminal Complement Inhibition ,Care Eculizumab ,Favorable Safety ,Paroxysmal Nocturnal Hemoglobinuria ,Residual Anemia ,New Orleans ,Accessed December ,Open Label Trial ,Evaluate Efficacy ,Twice Daily Iptacopan ,Who Are Naive ,Complement Inhibitor ,Active Comparator Controlled ,Twice Daily ,Adult Patients With ,Treatment With ,Intravenous Anti C ,Transfus Cell ,Rev Dis ,Novel Classification ,Identify Unmet Clinical Needs ,Future Clinical ,Natl Acad ,Parallel Group ,Placebo Controlled Study ,Primary Iga Nephropathy ,Rare Pediatric Disease Designation ,Accessed September ,Dharma ,Presents ,Pivotal ,Hase ,Apply ,Data ,Emonstrating ,Investigational ,Mural ,Monotherapy ,Iptacopan ,Superiority ,Dover ,Anti ,